The effect of formalizing enhanced recovery after esophagectomy with a protocol.
Findlay JM. et al, (2015), Dis Esophagus, 28, 567 - 573
The effect of formalizing enhanced recovery after esophagectomy with a protocol
Findlay JM. et al, (2015), Diseases of the Esophagus, 28, 567 - 573
A phase I dose-escalating and safety study of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophago-gastric adenocarcinoma
Thomas AL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
A phase Ib study of investigational pan-RAF kinase inhibitor MLN2480 plus investigational TORC1/2 inhibitor MLN0128, investigational Aurora A kinase inhibitor alisertib (MLN8237), or paclitaxel in patients (pts) with advanced solid tumors.
Olszanski AJ. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.
Van Schaeybroeck S. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Phase I study of the PI3K/mTOR inhibitor PF-05212384 in combination with other antitumor agents.
Wainberg ZA. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
Seropositivity to tumour antigens as a potential new biomarker for melanoma relapse.
Clark LL. et al, (2015), JOURNAL OF CLINICAL ONCOLOGY, 33
A systematic review and meta-analysis of somatic and germline DNA sequence biomarkers of esophageal cancer survival, therapy response and stage.
Findlay JM. et al, (2015), Ann Oncol, 26, 624 - 644
Assessment of the drug interaction potential and single- and repeat-dose pharmacokinetics of the BRAF inhibitor dabrafenib.
Suttle AB. et al, (2015), J Clin Pharmacol, 55, 392 - 400
Decision theory and cost-benefit analysis of re-staging oesophageal cancer after neoadjuvant chemotherapy with PET-CT rather than CT
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 41 - 41
FDG-avid nodal stage of oesophageal cancer and response to neoadjuvant chemotherapy: new classifications predicting disease progression before surgery, and early recurrence afterwards
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 44 - 44
Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer.
Bendell J. et al, (2015), Ann Oncol, 26, 804 - 811
The impact of oesophageal cancer temporal heterogeneity on DNA markers, drivers and targets, and the development of a combined clinical, genomic, pathological and radiological framework
Findlay JM. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 24 - 25
NY-ESO-1 specific antibody and cellular responses in melanoma patients primed with NY-ESO-1 protein in ISCOMATRIX and boosted with recombinant NY-ESO-1 fowlpox virus.
Chen J-L. et al, (2015), Int J Cancer, 136, E590 - E601
O6.4VX-970, selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein.
Asmal M. et al, (2015), Ann Oncol, 26 Suppl 2
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel.
Coupe N. et al, (2015), Eur J Cancer, 51, 359 - 366
Genomic Biomarkers of Oesophageal Cancer Survival and Response to Therapy
Findlay J. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 164 - 164
Restaging Oesophageal Cancer Following Neoadjuvant Chemotherapy With Pet-Ct, and Prediction Of Progression to Unresectable Disease
Findlay J. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 7 - 7
Selective Staging of Oesophageal and Gastro-Oesophageal Junctional Cancer with Endoscopic Ultrasound, Positron Emission Tomography and Laparoscopy
Findlay J. et al, (2015), BRITISH JOURNAL OF SURGERY, 102, 34 - 35